术中地塞米松使用是否与全关节置换术后假体周围关节感染率增加相关
基于2015至2020年全国数据库1,322,025例初次择期全关节置换患者,比较术中接受与未接受地塞米松者的90天感染并发症风险。全膝关节置换中地塞米松与假体周围关节感染风险降低相关(调整比值比0.87,95%CI 0.82-0.93,P<.001),全髋关节置换中同样相关(调整比值比0.80,95%CI 0.73-0.86,P<.001)。结论认为术中地塞米松未增加感染并发症风险。
要点
- 全膝关节置换中,术中地塞米松与假体周围关节感染风险降低相关(调整比值比0.87,95%CI 0.82-0.93,P<.001)。
- 全髋关节置换中,术中地塞米松与假体周围关节感染风险降低相关(调整比值比0.80,95%CI 0.73-0.86,P<.001)。
- 术中地塞米松未与感染并发症风险增加相关,数据支持初次全膝关节或全髋关节置换术中使用地塞米松。
核心结论
- 术中地塞米松未与感染并发症风险增加相关,所提供数据支持初次全膝关节置换或全髋关节置换术中地塞米松的使用。
研究设计与样本
- 使用全国数据库识别2015年至2020年间接受初次择期全膝关节置换和全髋关节置换的成人,比较术中接受与未接受地塞米松的患者。
- 共1,322,025例患者接受初次择期全关节置换,其中857,496例(64.1%)接受全膝关节置换,474,707例(35.9%)接受全髋关节置换(原文此处两处均写作TKA,按上下文第二处应为THA)。
- 主要终点为90天感染并发症风险,次要终点包括血栓栓塞、肺部、肾脏和伤口并发症,采用多因素分析评估队列间所有终点的风险。
主要发现
- 全膝关节置换患者中,地塞米松与假体周围关节感染风险降低相关(调整比值比0.87,95%CI 0.82-0.93,P<.001),并与肺栓塞、深静脉血栓和急性肾损伤等次要终点相关。
- 全髋关节置换患者中,地塞米松与假体周围关节感染风险降低相关(调整比值比0.80,95%CI 0.73-0.86,P<.001),并与肺栓塞、深静脉血栓、急性肾损伤和肺炎等次要终点相关。
临床怎么用
- 原文结论指出,所提供数据支持初次全膝关节置换或全髋关节置换术中地塞米松的使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraoperative dexamethasone can reduce postoperative pain and nausea following total knee (TKA) and total hip arthroplasty (THA). To the best of our knowledge, no study to date has been adequately powered to detect the risk of periprosthetic joint infection (PJI) from early dexamethasone exposure. This study aimed to assess PJI rates and complications in patients undergoing primary elective TKA and THA who received intraoperative dexamethasone. METHODS: A national database was used to identify adults undergoing primary elective TKA and THA between 2015 and 2020. Patients who received intraoperative dexamethasone and those who did not were identified. The primary endpoint was 90-day risk of infectious complications. Secondary end points included thromboembolic, pulmonary, renal, and wound complications. Multivariate analyses were performed to assess the risk of all endpoints between cohorts. Between 2015 and 2020, 1,322,025 patients underwent primary elective TJA, of which 857,496 (64.1%) underwent TKA and 474,707 (35.9%) underwent TKA. RESULTS: In patients who underwent TKA, dexamethasone was associated with lower risk of PJI (adjusted odds ratio: 0.87, 95% CI: 0.82-0.93, P < .001) as well as other secondary endpoints such as pulmonary embolism, deep vein thrombosis, and acute kidney injury. In patients who underwent THA, dexamethasone was associated with a lower risk of PJI (adjusted odds ratio: 0.80, 95% CI: 0.73-0.86, P < .001) as well as other secondary endpoints such as pulmonary embolism, deep vein thrombosis, acute kidney injury, and pneumonia. CONCLUSION: Intraoperative dexamethasone was not associated with increased risk of infectious complications. The data presented here provide evidence in support of intraoperative dexamethasone utilization during primary TKA or THA.
引用
- Heckmann ND, Wang JC, Piple AS, et al. Is Intraoperative Dexamethasone Utilization Associated With Increased Rates of Periprosthetic Joint Infection Following Total Joint Arthroplasty? J Arthroplasty. 2022. PMID: 36031084. doi:10.1016/j.arth.2022.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。